Doceree Wins Silver at Cannes Lions 2025
Setting a new benchmark for creativity and innovation in global healthcare, the DawAI Reader by Alkem, is a powerful AI-based tool designed to read and decode handwritten prescriptions for patients in rural and remote parts of India—where access to pharmacists or educated interpreters is limited. By enabling people to understand the medicines prescribed to them in their local language, the innovation bridges a crucial gap in the care continuum, thereby significantly elevating healthcare outcomes in rural
The win underscores the growing leadership in healthtech innovation and highlights how collaborations between creativity, technology, and healthcare can drive transformative impact. It also signals a shift in the global narrative—one where technology is driving life-changing ideas.
About Doceree
Leading the way in making HCP-patient conversations richer and more meaningful through patented responsive technology, Doceree addresses both current and emerging challenges for healthcare and life sciences organizations in HCP-patient engagement, particularly where digital and technological advancements play a crucial role. We leverage our patented technology to ensure that HCP-patient conversations and interactions are more meaningful, richer, and outcome-oriented.
Learn more: www.doceree.com.
About DawAI Reader by Alkem
The DawAI Reader is an AI-powered tool by Alkem Laboratories that translates handwritten prescriptions into simple, local-language instructions. Designed for rural
Photo: https://mma.prnewswire.com/media/2712844/Doceree_Cannes_Lions_2025.jpg
Logo: https://mma.prnewswire.com/media/1758952/Doceree_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/doceree-wins-silver-at-cannes-lions-2025-302483851.html
SOURCE Doceree Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 15 Press Releases You Need to See This Week
- WELL Health to Present at The Cantech Investment Conference on October 8 in Toronto
- Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share